Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies
Stock Information for Immunome Inc.
Loading
Please wait while we load your information from QuoteMedia.